阿尔茨海默病的呼吸系统功能障碍 - - 后果还是根本原因? 将动物模型应用于呼吸系统功能障碍的研究
Agnieszka Wrzesień1, Kryspin Andrzejewski1, Monika Jampolska1
1Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.
International journal of molecular sciences
|February 24, 2024
概括
阿尔茨海默病 (AD) 与阻塞性睡眠呼吸暂停 (OSA) 等呼吸系统问题有关. 本综述侧重于动物模型,以了解与阿尔茨海默病相关的呼吸系统障碍,并指导未来的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 呼吸系统医学 呼吸系统医学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是老年人痴呆的主要原因.
- 阿尔茨海默病患者经常出现呼吸系统问题,包括肺炎,呼吸短促,肌肉虚弱和阻塞性睡眠呼吸暂停 (OSA).
- OSA被认为是AD的结果和潜在原因,突出了复杂的双向关系.
研究的目的:
- 为了对阻塞性睡眠呼吸暂停和阿尔茨海默病之间的双向关系进行叙事审查.
- 总结有关阿尔茨海默病患者呼吸系统疾病的现有研究.
- 专门审查使用动物模型的AD研究以调查呼吸系统障碍的研究.
主要方法:
- 在文献中搜索有关阿尔茨海默病,痴呆症,呼吸系统疾病和阻塞性睡眠呼吸暂停的研究.
- 专注于叙事审查方法.
- 包括使用动物模型来研究与AD相关的呼吸系统问题的研究.
主要成果:
- 该审查涉及已知的阿兹海默症患者的呼吸道并发症,如OSA.
- 它强调了使用动物模型进行研究的稀缺性,但对于理解AD相关的呼吸机制至关重要.
- 总结了现有的动物模型研究,以建立当前的知识.
结论:
- 动物模型对于阐明AD中呼吸系统障碍的机制和原因至关重要.
- 用动物模型进行的研究对于开发和测试阿兹海默症患者呼吸系统疾病的潜在疗法至关重要.
- 需要使用动物模型进行进一步的研究,以弥合AD患者的基本科学和临床应用之间的差距.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Acute Respiratory Failure-III
185
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
185
